Complete patient enrollment for the Phase 3 APOLLO study

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 13 Feb 2026
Due: 31 Mar 2026
Delivered: March 2026

Deadline
Met
Late
Not met
Today

What the company said

“allowing Disc to complete trial enrollment in March 2026”

SourceDisc Medicine, Inc. Form 8-K press release, 2026-02-13
FilingSEC filing index
Deadline as statedMarch 2026
Deadline used31 Mar 2026, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2026-IRON-002226
Cite as https://keptindex.org/c/KI-C-2026-IRON-002226/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company confirmed in its May 2026 filing that it had completed enrollment for the Phase 3 APOLLO study, meeting the March 2026 deadline.

A
Disc Medicine, Inc. 8-K filed 2026-05-05 Regulatory filing · published 5 May 2026 · retrieved 1 Oct 2026 · kept permanently by the SEC
“Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)” ✓ confirmed on the page

Market reaction: the shares moved -2.1% against the S&P 500 over the three sessions around the disclosure (4 May 2026 to 7 May 2026). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 13 Feb 2026

Deadline 31 Mar 2026 (“March 2026”)
Version 2 · stated 26 Feb 2026

Deadline 31 Mar 2026 (“March 2026”) · wording expected

“Phase 3 APOLLO study is expected to complete enrollment in March 2026”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Complete
Deliverable: APOLLO study enrollment
In the company’s control: Medium
Specificity: High
Depends on: Customer

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.